查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
青光眼治疗市场：2023年至2028年预测
市场调查报告书
商品编码
1410100

青光眼治疗市场：2023年至2028年预测

Glaucoma Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年青光眼治疗市场规模达20.47亿美元。

预计青光眼治疗市场在预测期内将显着成长。青光眼一词是指一组损害眼睛视神经的疾病。青光眼是最常见的视神经损伤类型，会导致视力丧失。主要治疗目标是降低眼压。这是透过减少房水的分泌或增加其排水来实现的。急性郁血性青光眼、慢性青光眼、隅角闭锁性青光眼和开放性青光眼是青光眼的其他类别。

青光眼治疗市场的主要成长动力

青光眼盛行率的增加、医疗费用的上升、诊断技术的改进、有利的报销实践等都促进了青光眼治疗市场的成长。此外，新药物配方的可得性和青光眼治疗技术的开拓，例如微创青光眼手术（MIGS）设备和缓释性药物输送系统，正在推动青光眼治疗市场的扩张。

青光眼患者增加

青光眼盛行率的增加预计将影响青光眼治疗市场。根据美国国家医学图书馆的数据，60 岁以上的人、已被诊断患有青光眼的人的家庭成员、类固醇使用者、患有糖尿病、高度近视、高血压和中央角膜的人是青光眼的高危险群。厚度5毫米。低于100%，如伤眼。预计2020年将有7,600万人患有青光眼，到2040年将增加到1.118亿。

预计老年人口的增加将提振市场。

人口老化将显着推动青光眼治疗市场的发展。老龄化相关的因素增加了青光眼的盛行率，导致新药的需求增加以及与眼部保健相关的医疗费用增加。此外，根据 2017 年联合国报告，预计该疾病的盛行率在未来几年将会上升，60 岁及以上人口将从 2017 年的 12.7% 增加到 2050 年的 21.3%。老年人常遇到各种健康问题，包括青光眼与其他老龄化相关疾病并存，因此需要彻底、全面的治疗方法。

Gland素类似物预计将大幅成长

Gland素类似物对于控制眼压和延迟发病至关重要，对青光眼治疗市场有重大影响。青光眼治疗行业由于其广泛使用和患者依从性的提高而整体增长，因为与某些替代方案相比，其优越的疗效和较低的副作用。Gland类似物的广泛使用正在影响市场动态和治疗模式，并刺激青光眼治疗的研究和开发。

预计技术进步将刺激青光眼治疗市场

市场形势的技术进步彻底改变了形势，为诊断、监测和治疗性介入提供了创新的解决方案。对创新手术方法的需求预计将推动青光眼治疗市场的成长。医学影像、光同调断层扫瞄（OCT）、微创青光眼手术（MIGS）、选择性雷射海绵体成形术（SLT）和进展分析软体的进步将进一步增加对验光师的需求。

对高效青光眼处方眼药水的需求不断增长

青光眼治疗市场的市场参与企业和主要参与企业正在努力开发创新药物组合和处方眼药水，以儘早控制青光眼。一些生物医学和製药公司正在致力于产品开发，以减轻医疗机构的负担。这些用于治疗青光眼的药物包括β阻断剂、碳酸酐酶抑制剂、α促效剂、胆碱能促效剂、Gland类似物 (PGA) 和某些联合治疗。这些药物透过促进液体从患者眼睛中排放帮助降低眼内压。

管道疗法代表着巨大的市场机会

针对当前疾病的各种管道治疗是预测期内青光眼治疗市场成长的主要驱动力。其中之一是由明尼苏达大学药学院治疗发现与开发研究所 (ITDD) 和药物化学系开发的一种用于治疗青光眼的全新药物。正在开发的主要青光眼治疗药物有拉坦前列素、盐酸利帕舒地尔水合物、PH-011、PH-012、甲磺酸奈达舒地尔、拉坦前列素、（Bimatoprost+噻吗洛尔）和（拉坦前列素+奈达舒地尔）。

预计北美市场将显着成长

北美青光眼治疗市场成长的关键因素之一是先进的医院诊断基础设施和高效的治疗系统。此外，该地区不断增加的 FDA核准和药物上市也支持了成长。

市场主要发展

2023 年 4 月，三一学院的遗传学家开发了一种治疗青光眼的新基因疗法。 2022年7月，艾伯维与iSTAR Medical达成策略协议，将MINIject®设备商业化，这是一种针对青光眼患者的微创青光眼手术器械。 2022年4月，Skye Bioscience选择CMAX临床研究进行SBI-100眼用乳剂的1期研究。 Skye 得到了 CMAX 的支持，CMAX 是世界上最着名的专门从事早期试验的临床实验运营商之一。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章青光眼治疗市场：依疾病类型

  • 介绍
  • 开放性青光眼
  • 隅角闭锁性青光眼
  • 其他的

第六章青光眼治疗市场：依药物类别

  • 介绍
  • Gland类似物
  • β 受体阻断药
  • 肾上腺素能促效剂
  • 碳酸酐酶抑制剂
  • 其他的

第七章青光眼治疗市场：按分销管道

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第八章青光眼治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Novartis AG
  • Alcon Inc.
  • Akron Operating Company LLC
  • Thea Pharma
  • AbbVie, Inc.
  • Bausch+Lomb Corporation
  • Teva Pharmaceuticals Industries Ltd.
  • AC Immune
简介目录
Product Code: KSI061615756

The glaucoma treatment market was valued at US$2.047 billion in 2021.

The glaucoma treatment market is anticipated to grow significantly during the forecast period. The term glaucoma refers to a collection of conditions that harm the optic nerve in the eyes. It is the most typical type of optic nerve injury that results in visual loss. Lowering intraocular tension is the major treatment objective. This is accomplished by either decreasing aqueous humour secretion or enhancing drainage. Acute congestive glaucoma, chronic glaucoma, angle-closure glaucoma, and open-angle glaucoma are other categories of glaucoma.

Major growth drivers for the glaucoma treatment market

The increased prevalence of glaucoma, rising healthcare costs, improvements in diagnostic techniques, and favourable reimbursement practices are all contributing to the growth of the glaucoma treatment market. In addition, the availability of novel medication formulations and technical developments in glaucoma therapies, such as minimally invasive glaucoma surgery (MIGS) devices and sustained-release drug delivery systems, are propelling the glaucoma treatment market's expansion.

Increasing prevalence of people suffering from glaucoma

The growing prevalence of glaucoma among people is anticipated to impact the glaucoma treatment market. According to the National Library of Medicine, a higher risk of glaucoma is associated with elderly over 60, family members of those already diagnosed with the condition, steroid users, diabetics, high myopia, hypertension, central corneal thickness less than 5 mm, and ocular trauma. It is projected that 76 million individuals had glaucoma in 2020, and by 2040, the figure is anticipated to rise to 111.8 million.

Growth in the geriatric population is predicted to fuel the market.

The market for glaucoma treatments is greatly boosted by the aging population as age-related factors increase the prevalence of glaucoma, which in turn drives demand for novel medicines and raises healthcare costs associated with eye care. Furthermore, according to a 2017 United Nations report, the prevalence of the disease is predicted to rise in the coming years as the population aged 60 and above rises from 12.7% in 2017 to 21.3% by 2050. A thorough and integrated approach to therapy is required since the senior population frequently experiences various health issues, including the coexistence of glaucoma with other age-related disorders.

Prostaglandin Analogs is anticipated to grow significantly

Prostaglandin analogues, which are essential for controlling intraocular pressure and delaying the onset of the condition, have had a significant effect on the market for glaucoma treatments. The glaucoma pharmaceutical industry has grown as a whole and patient compliance has risen as a result of its widespread usage due to its excellent effectiveness and low adverse effect profile when compared to certain alternatives. Prostaglandin analogues' widespread use has impacted market dynamics and treatment patterns and has fueled glaucoma therapy research and development.

Advancements in technology are predicted to fuel the glaucoma treatment market

Technological advancements in the glaucoma treatment market have revolutionized the landscape, providing innovative solutions for diagnosis, monitoring, and therapeutic interventions. The demand for innovative surgical methods is anticipated to fuel glaucoma treatment market growth. The advancements in medical imaging, optical coherence tomography (OCT), micro-invasive glaucoma surgery (MIGS), selective laser trabeculoplasty (SLT), and progression analysis software further increase the demand for optometrists.

Growing demand for efficient prescription eye drops for glaucoma

Manufacturers and major market participants in the glaucoma treatment market are working to develop innovative medication combinations and prescription eye drops to control glaucoma at an early stage. To ease the burden on healthcare facilities, several biomedical and pharmaceutical companies engage in product development. Several of these medications used to treat glaucoma include beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cholinergic, prostaglandin analogues (PGAs), and certain combination treatments. These drugs assist in reducing intraocular pressure by encouraging fluid evacuation from the patient's eye.

Pipeline therapy is a major market opportunity

The various pipeline therapies for the currently developing disease are the primary drivers of the glaucoma treatment market growth over the forecast period. One such development is a brand-new medicine for the treatment of glaucoma that was developed by the Institute for Therapeutics Discovery & Development (ITDD) and the Department of Medicinal Chemistry at the University of Minnesota College of Pharmacy. The leading glaucoma drugs in development were latanoprost, ripasudil hydrochloride hydrate, PH-011, PH-012, netarsudil mesylate, latanoprost, (bimatoprost + timolol), and (latanoprost + netarsudil).

North America is anticipated to show significant growth in the market

One of the main factors contributing to North America's glaucoma treatment market growth is its sophisticated hospital diagnosis infrastructure and efficient treatment framework. Furthermore, the growth is being supported by the increasing number of FDA approvals and medicine launches for the treatment in the area.

Market Key Developments

  • In April 2023, new novel gene therapy for glaucoma was developed by Trinity College geneticists.
  • In July 2022, AbbVie and iSTAR Medical formed a strategic agreement to commercialise the MINIject® device, a less invasive glaucoma surgical tool for glaucoma patients.
  • In April 2022, to carry out the Phase 1 study for SBI-100 Ophthalmic Emulsion, Skye Bioscience chose CMAX clinical research. Skye got assistance from CMAX, one of the most renowned trial operators in the world which specialises in early-phase studies.

Segmentation:

By Disease Type

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

By Drug Class

  • Prostaglandins Analogs
  • Beta-blockers
  • Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLAUCOMA TREATMENT MARKET BY DISEASE TYPE

  • 5.1. Introduction
  • 5.2. Open Angle Glaucoma
  • 5.3. Angle Closure Glaucoma
  • 5.4. Others

6. GLAUCOMA TREATMENT MARKET BY DRUG CLASS

  • 6.1. Introduction
  • 6.2. Prostaglandins Analogs
  • 6.3. Beta-blockers
  • 6.4. Adrenergic Agonists
  • 6.5. Carbonic Anhydrase Inhibitors
  • 6.6. Others

7. GLAUCOMA TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online Pharmacy

8. GLAUCOMA TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Pfizer Inc.
  • 10.2. Santen Pharmaceutical Co., Ltd.
  • 10.3. Novartis AG
  • 10.4. Alcon Inc.
  • 10.5. Akron Operating Company LLC
  • 10.6. Thea Pharma
  • 10.7. AbbVie, Inc.
  • 10.8. Bausch + Lomb Corporation
  • 10.9. Teva Pharmaceuticals Industries Ltd.
  • 10.10. AC Immune